Rosy prospects of Russian medicine and pharmacology
The future of Russian innovative medicine and pharmaceutical industry
it became the subject of discussion at the Congress of Nanotechnologists in Moscow
A separate panel discussion was held on these issues "How to create a domestic innovative infrastructure of the medical and pharmaceutical industry, competitive at the global level?".
Socially significant industries, which, of course, include the production of medical equipment and medicines, should be a priority for entrepreneurs specializing in high-tech developments. However, largely due to the same social significance, business in this area faces great difficulties. Innovative products must pass multiple tests and trials (preclinical and clinical) before they get into clinics or retail sale. As a rule, this process takes years and requires considerable investments. All this entails great risks for entrepreneurs and investors, and, as a result, slows down the development of the industry.
"It is important that Russia begins to create new medicines that will be applicable not only in our country, but throughout the world. Only under this condition will investments in the creation of new pharmaceutical technologies pay off and Russia will become a place of concentration of highly intelligent and highly paid human resources. At the same time, taxes on royalties from receipts from many countries of the world for the use of intellectual rights to new Russian medicines will become a serious contribution to the state treasury," said Leonid Melamed, one of the leading experts in the field of nanomedicine, who also moderated the discussion.
The speeches of the invited speakers were devoted to various aspects of the functioning of high-tech enterprises in medicine and pharmacology.
Grigory Borisenko, Investment Director of RUSNANO Management Company LLC, said that, according to research, the healthcare sector was recognized as the second most efficient investment, and gave examples of successful cooperation of RUSNANO Management Company with a number of Russian innovative companies, which resulted in the intensification of clinical trials and the introduction of new products to the market.
Vladimir Khristenko, President of Nanolek LLC, spoke in detail about the mechanisms of competition in both the domestic and global markets. In particular, he expressed confidence that only with the help of collaboration with major global manufacturers it is possible to achieve the efficiency of the export of Russian technologies. In particular, Mr. Khristenko noted that "the following factors can positively influence the development of the competitiveness of the domestic innovative pharmaceutical industry: global cooperation with international partners both in terms of the transfer of innovations to Russia and the export of domestic developments to other markets; long-term state support for the industry, consisting in the formation of transparent and unchangeable "rules of the game", forecasting and formation of demand, and the creation of tools to ensure it, for example, long–term contracts; accumulation of competencies in various areas of drug provision of healthcare - development, clinical research, production, etc.".
Dmitry Kolobov, Deputy Director of the Pharmaceutical and Medical Industry Development Department of the Ministry of Industry and Trade, invited industry representatives to use state support measures and spoke about innovations in the quality control system in pharmacology, which are designed to facilitate the further entry of Russian products into the foreign market.
Artur Isaev, General Director of the Human Stem Cell Institute, noted the improvement of competencies in the field of expertise and development in the domestic pharmaceutical industry, but agreed that Russian technologies are poorly prepared to enter the global market, linking this, among other things, with the discrepancy of technological standards and the lack of international certificates, as well as generally low efficiency of business processes in Russia.
Experts expressed their opinion on the issues raised:
Ivan Glushkov, Deputy Director for Business Development at STADA, called for creating demand for innovative pharmaceutical products in Russia using effective state support mechanisms.
Roman Bolgarin, Director of Project Activities, Niarmedic Plus LLC, Member of the Management Board of NP Kaluga Pharmaceutical Cluster, drew the attention of colleagues to the lack of mechanisms for mutual recognition of research results and certification in Russia and abroad.
In general, the participants of the discussion noted the high potential of the industry. Provided that a number of key problems, including personnel problems, are solved, the increase in the effectiveness of Russia's presence on the world market of medicines and medical products should manifest itself in the coming years.
The participants of the discussion also suggested an increase in the efficiency of investing medicine and pharmacology in the case of a more understandable interaction with potential customers and the development of an insurance financing system for the pharmaceutical industry. In addition, the experts expressed hope for the active participation of business representatives in the discussion and preparation of key bills regulating the activities of the industry.
The organizers of this discussion expressed the hope that the concrete solutions developed by the participants could contribute not only to the implementation of the import substitution program and the stabilization of the domestic market, but also bring Russia into the largest players in the global market of medical products and pharmaceutical industry, allowing us to start actively exporting our technologies around the world.
Portal "Eternal youth" http://vechnayamolodost.ru
11.12.2015